You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
翰森製藥(03692.HK)與韓國交易所上市公司OliX Pharamceuticals訂立獨家許可合作協議
格隆匯 10-12 07:57

格隆匯10月12日丨翰森製藥(03692.HK)發佈公吿,2021年10月11日,翰森(上海)健康科技有限公司及江蘇豪森藥業集團有限公司(統稱為“被許可人”,各自為公司的全資附屬公司),已與OliX Pharmaceuticals, Inc. (KOSDAQ: 226950)(“OliX Pharamceuticals”)訂立獨家許可合作協議。

根據許可協議,OliX Pharmaceuticals將利用GalNAc-asiRNA平台技術,以發現先導藥物並確保針對與肝臟相關的心血管、代謝及其他疾病的靶點的候選藥物開發。翰森將擁有這些療法在中國(包括中國香港、中國澳門及中國台灣)的獨家商業權益,OliX Pharmaceuticals將擁有該地域以外其他地區的權益。OliX Pharmaceuticals將收到650萬美元的首付款,以及基於重要里程碑最高為4.5億美元的款額與特許權許可分成。

有見於OliX Pharmaceuticals為一家在siRNA研發領域具有領先地位及具有成熟的臨牀階段組合的製藥公司,公司預期將利用其創新技術平台針對肝臟相關靶點進行藥物研發,以解決廣泛的未被滿足的臨牀需求,涉及領域包括心血管疾病、代謝疾病及其他疾病等。OliX Pharmaceuticals是一家臨牀階段的製藥公司,利用其獨有的RNA干擾技術,通過下調疾病致病基因的表達,開發療法治療多種疾病。OliX Pharmaceuticals是一家在韓國交易所上市的公司(KOSDAQ: 226950)。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account